Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants-Reference-Cited by-同舟云学术

Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants

Published:2018-01-17 Issue:7 Volume:187 Page:1490-1500
ISSN:0002-9262
Container-title:American Journal of Epidemiology
language:en
Short-container-title:

Author:

Wu Pingsheng¹²,Escobar Gabriel J³⁴,Gebretsadik Tebeb²,Carroll Kecia N⁵,Li Sherian X⁴,Walsh Eileen M⁴,Mitchel Edward F⁶,Sloan Chantel⁷,Dupont William D²⁶,Yu Chang²,Horner Jeffrey R²,Hartert Tina V¹

Affiliation:

1. Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

2. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee

3. Department of Inpatient Pediatrics, Kaiser Permanente Medical Center, Walnut Creek, California

4. Perinatal Research Unit, Division of Research, Kaiser Permanente Northern California, Oakland, California

5. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee

6. Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee

7. Department of Health Science, College of Life Sciences, Brigham Young University, Provo, Utah

Funder

Agency for Healthcare Research and Quality

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Epidemiology

Link

http://academic.oup.com/aje/article-pdf/187/7/1490/25076740/kwy008.pdf

Reference41 articles.

1. Risk of primary infection and reinfection with respiratory syncytial virus;Glezen;Am J Dis Child,1986

2. Respiratory syncytial virus and parainfluenza virus;Hall;N Engl J Med,2001

3. Bronchiolitis-associated hospitalizations among US children, 1980–1996;Shay;JAMA,1999

4. Respiratory syncytial virus immune globulin intravenous: indications for use;American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn;Pediatrics,1997

5. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection;American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee;Pediatrics,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MFGM-enriched whey displays antiviral activity against common pediatric viruses in vitro;Frontiers in Nutrition;2024-07-31

2. Personalized Infant Risk Prediction for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Requiring Intensive Care Unit Admission;Open Forum Infectious Diseases;2024-02-06

3. Impact of Palivizumab in Preventing Severe Acute Lower Respiratory Infection in Moderate-to-Late Preterm Infants: A Nationwide Cohort Study;Journal of Korean Medical Science;2024

4. Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection;Pediatrics;2023-06-26

5. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study;The Lancet;2023-05